Allon Therapeutics selected by the Alzheimer's Disease Cooperative Study
The ADCS has indicated that the selected programs will be submitted as a grant application to the NIH in October and a final funding decision made by the NIH in Q1 2006. It is possible that the whole grant application or components parts of it may not be approved. The ADCS was established in 1991 and has become the largest recipient of U.S. government funding for Alzheimer's research and clinical trials.
Allon announced March 2, 2005 that it had completed dosing for its Phase Ia human clinical trial evaluating AL-108 as a treatment for Alzheimer's disease. Data from the Phase Ia trial will be analyzed by the end of the second quarter. The next clinical development step for AL-108 is a Phase Ib trial to evaluate AL-108 in healthy adults most at risk for Alzheimer's disease, and ultimately in diagnosed Alzheimer's patients, subject to appropriate regulatory approval. Allon has shown in preclinical studies that AL-108 has activity that may reduce plaque and tangle formation, removes plaques and promotes the repair of neurofibrillary tangles. AL-108 may also protect healthy neurons from damage cause by the formation of plaques and tangles.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.